INPROTHER 

A paradigm shift in immunotherapy. Targeting the Human Endogenous Retroviruses to Treat Cancer

OWNER

JORDDI NAVAL (See Profile)


Sector

Biotech

Stage

Prototyping, preclinical

Country

Denmark


HERVS are known as tumor specific antigens, but they have been undruggable until now

HERVS are recognized as tumor specific antigens, but they have been undruggable until now

And we are doing so one HERV at a time

InProTher has designed the optimal immunogen delivered in the right modality (Adenoviral and RNA vectors)

We will be able to treat multiple cancers, alone or in combination with checkpoint inhibitors

Status

Approved

IP Type

Patent

Time

20 years

Countries

Australia
Austria
Belgium
Denmark
Finland
France
Germany
Japan
Netherlands
Russia
South Korea
Spain
Switzerland
USA
United Kingdom

Coverage

The design of the HERV immunogen to treat cancer

Know more of this patent

This information is confidential, do not share or copy.

Under evaluation at least till: 12th of April 2022

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2022 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar